Biotech

All Articles

Lykos will definitely ask FDA to rethink its choice adhering to rejection of MDMA therapy for trauma

.Adhering to a poor showing for Lykos Rehabs' MDMA candidate for trauma at a current FDA advising co...

AN 2 one-halfs roll call, quits stage 3 test after records dissatisfy

.AN2 Therapeutics is actually reassessing its own business in feedback to dull midphase records, vow...

Merck pays for $700M for bispecific, spying autoimmune position as well as opportunity to challenge Amgen in cancer cells

.Merck &amp Co. is paying out $700 million upfront to test Amgen in a blood cancer market. The barga...

Gilead pays for J&ampJ $320M to leave licensing deal for seladelpar

.Along With Gilead Sciences almost an FDA choice for its liver illness medicine seladelpar, the busi...

' All palms on deck' at Lilly as peers target obesity market

.CEO David Ricks can find the providers putting together tents at basecamp responsible for Eli Lilly...

Entero giving up team, leaving workplace and pausing R&ampD

.Bed Liquidators has actually turned Entero Therapeutics white as a piece. The financial institution...

Exelixis drops ADC after choosing it's no match for Tivdak

.Exelixis is actually losing hope on its own tissue element (TF)- targeting antibody-drug conjugate ...

Relay dislikes SHP2 prevention after Genentech leaves behind

.Three weeks after Roche's Genentech unit left an SHP2 prevention deal, Relay Rehab has actually con...

Stoke's Dravet disorder med discharged of partial scientific hold

.Stoke Rehabs' Dravet syndrome drug has been without a predisposed grip, getting rid of the method f...

Fierce Biotech's Gabrielle Masson shows Tough 15 at NYSE

.Ferocious Biotech Colleague Editor Gabrielle Masson showed the 2024 training class of Fierce 15 win...